The use of multiple ion chains in a single ion trap for quantum information processing (QIP) systems is described. Each chain can have its own set of laser beams with which to implement and operate quantum gates within that chain, where each chain may therefore correspond to a single quantum computing register or core. Operations can be performed in parallel across all of these chains as they can be treated independently from each other. To implement and operate quantum gates between different chains, neighboring chains are merged into a single, larger chain, in which one can perform quantum gates between any of the ions in the larger chain. The combined chains can then be separated again by another shuttling event as needed. To implement and operate quantum gates between ions which do not occupy neighboring chains, swap gates can be used via a sequence of intervening chains.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
2.
COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
An insufflation system for creating a high-flow, constant pressure pneumoperitoneum, the system including: a gas flow distribution device including: a housing defining an insufflation chamber; an inlet port on the housing and configured to be connected to an insufflator to provide insufflation gas from the insufflator to the insufflation chamber; and a plurality of outlet ports on the housing configured to be connected to a plurality of trocars, each outlet port configured to be connected to a dedicated one of the plurality of trocars, to concurrently distribute the insufflation gas from the insufflation chamber to each of the plurality of trocars.
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Zalutsky, Michael
Feng, Yutian
Vaidyanathan, Ganesan
Zeglis, Brian
Sarrett, Samantha
Abrégé
The present disclosure provides, in part, methods for site-specific labeling of proteins/peptides with radiohalogens and compositions resulting from said methods.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07D 271/113 - Oxadiazoles-1, 3, 4; Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
A61K 51/10 - Anticorps ou immunoglobulines; Leurs fragments
Disclosed are high density POEGMA-biologically active agent conjugates that have advantageous pharmacokinetics, while also having a reduced or eliminated host-immune response. An example conjugate includes a biologically active agent and a plurality of POEGMA molecules conjugated to the biologically active agent, each POEGMA molecule having a poly(methyl methacry late) backbone and a plurality of side chains covalently attached to the backbone, each side chain including 2 to 9 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of reducing the immunogenicity of a polymer-biologically active agent conjugate.
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
7.
ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (Royaume‑Uni)
Inventeur(s)
Li, Dapeng
Mcmichael, Andrew James
Brackenridge, Simon
Gillespie, Geraldine
Azoitei, Mihai
Walters, Lucy C.
Saunders, Kevin O.
Haynes, Barton F.
Abrégé
The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and. regulate the cytotoxicity effector cell function of NK and/or CD8+ T-cells positive for cell-surface expression of NKG2A ("NKG2A+"). Herein, monoclonal antibodies were recombinant.lv derived from isolated functional HLA-E- VL9-specific mAbs from HLA-E- VL9 peptide- immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity' and can preferentially recognize HLA-E- VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity7 maturation. The invention provides methods for using affinity matured HLA-E- VL9 mAbs to modulate NK and/or CD8+T- cell function as part of immunotherapeutic strategies.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
8.
LAYERED DOUBLE HYDROXIDE PARTICLES IN HYDROGEL MATRICES
Exemplary layered double hydroxides (LDHs) may comprise a compound of formula Mg4-yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01 = y = 1. Exemplary layered double hydroxide hydrogels (LDH-gels) may comprise a hydrogel and at least one LDH. Exemplary hydrogels may comprise polyethylene (glycol) diacrylate (PEGDA) or polyacrylamide (PAAm). Exemplary LDH-gels may comprise at least one LDH comprising a compound of formula Mg4-yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01 = y = 1.
System and method for volume reduction solids treatment for fecal waste are described. The system can include a pasteurizer (102) configured to receive a slurry batch and heat the slurry batch at an elevated temperature for a time period to produce a pathogen free slurry. The system can also include a mechanical dewatering press (104) configured to compress the pathogen free slurry to separate a liquid phase from a volume reduced solid waste. The volume reduced solid waste being formed into a feces cake. The system can also include a means to remove the liquid phase and a drying tunnel (106) comprising a conveyor housed and an air duct system. The air duct system configured to propel forced air over the feces cake.
C02F 11/122 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par déshydratation mécanique à l’aide de filtres-presses
C02F 11/13 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par chauffage
10.
COMPOSITIONS FOR AND METHODS OF IMPROVING VIRAL VECTORS
Disclosed herein are viral vectors for use in methods of developing HDAC-depleted cells. Disclosed herein are methods of increasing packaging capacity, increasing the titer, increasing the expression capacity, and decreasing the immunogenicity and/or toxicity of an optimized viral vector generated in HDAC-depleted cells.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
Disclosed are compositions and methods that enable loop-mediated isothermal amplification (LAMP) of one or more nucleic acid targets without the need for conventional LAMP primer design customized to each target. A transduction reaction is performed upstream from the LAMP reaction. The transduction reaction generates a single stranded DNA (ssDNA) oligonucleotide when the target nucleic acid is present in the sample. The ssDNA generated in the transduction reaction functions as a required LAMP primer for a universal LAMP template. The ssDNA thus promotes the LAMP reaction. Analysis of the LAMP products can determine the presence of the one or more nucleic acid targets.
In one or more embodiments, the present invention provides a bottlebrush polymer for use with implantable synthetic intraocular lenses comprising a homopolymer or copolymer of a high reflective index methacrylate monomer or macromolecule such as monomethacryloxypropyl terminated polydimethylsiloxane, asymmetric (PDMS-MA), 2,2,2-trifluoroethyl methacrylate (TFEMA), oligo(ethylene glycol) methacrylate (OEGMA), 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluorodecyl methacrylate (HDFDMA), benzyl methacrylate (BzMA), 2-[3-(2H-Benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate (BzTAzMA), ethyleneglycol phenylether methacrylate (EGPhEMA), hydroxyethyl methacrylate (HEMA), or a combinations thereof having a refractive index and viscosity suitable for use as a filling material for implantable synthetic intraocular lenses.
The present disclosure provides compositions and methods related to the detection of pathogenic organisms. In particular, the present disclosure provides compositions and methods related to the detection and/or quantification of viral RNA in a sample from a subject that has, or is suspected of having, a SARS-CoV-2 infection. Using rapid reverse-transcription loop-mediated isothermal amplification (RT-LAMP), the compositions and methods of the present disclosure provide a portable, inexpensive, rapid, and accurate assay platform for detecting and/or quantifying the presence of a pathogenic organism (e.g., SARS-CoV-2) in a patient sample.
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
14.
HIV-1 ENVELOPE GLYCOPEPTIDE NANOPARTICLES AND THEIR USES
The invention is directed to coronavirus based immunogens, including immunogens comprising spike protein and or domains thereof, comprised in multimeric complexes. Provided are also methods of using these immunogens to induce immunogenic responses in a subject.
THE U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Steinbrink, Julie
Mcclain, Micah
Myers, Rachel
Johnson, Melissa
Tsalik, Ephraim
Alexander, Barbara
Woods, Christopher
Abrégé
The present disclosure provides methods for determining whether a subject has a fungal infection such as candidemia, or is at risk of developing the same, and methods of treating the subject based on the determination. This determining may include rapid detection of one or multiple pathogen classes at once, such as fungal, viral and bacterial. Systems useful for the same are also provided.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
17.
COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
This invention provides in general, a composition suitable for use in inducing anti-HIV-1 antibodies, such as immunogenic compositions comprising envelope proteins and nucleic acids to induce cross-reactive neutralizing antibodies and increase their breadth of coverage. The invention also provides methods of inducing such broadly neutralizing anti-HIV-1 antibodies using such compositions.
A61K 39/21 - Retroviridae, p.ex. virus de l'anémie infectieuse équine
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
18.
COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING GLYCOGEN STORAGE DISEASE TYPE VI AND TYPE IX
Glycogen storage disease (GSD) types VI and IX are caused by phosphorylase system de?ciencies and these GSDs are often clinically indistinguishable from one another. Disclosed herein are compositions for and methods of treating and/or preventing GSD VI and GSD IX disease progression with gene therapy alone or in combination with other therapies.
Disclosed herein are compositions for and gene therapy methods of treating and/or preventing glycogen storage disease progression including the progression of GSD IV and/or APBD. Also disclosed herein are compositions for and gene therapy methods of preventing glycogen accumulation and/or degrading accumulated glycogen.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p.ex. cellulases, lactases
20.
DROPLET ORGANOID-BASED IMMUNO-ONCOLOGY ASSAYS AND METHODS OF USING SAME
The present disclosure describes, in part, a Micro-organosphere immune-oncology assay and methods of making and using same. The assay quickly measures the potency of effector immune cells, such as tumor infiltrating lymphocytes, at killing a patient's tumor cells. Understanding the potency of effector immune cells is critical for adoptive T cell therapy.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
21.
TARGETED GENE REGULATION OF HUMAN IMMUNE CELLS WITH CRISPR-CAS SYSTEMS
Disclosed herein are CRISPR/Cas systems comprising a fusion protein and at least one gRNA targeting a gene or a regulatory element thereof in a cell such as an immune cell, and vector compositions encoding the same. The systems and compositions may be used in methods of modulating expression of a gene in a cell such as an immune cell, as well as in methods of treating a disease such as cancer, autoimmune diseases, or viral infections.
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
22.
COMPOSITIONS AND METHODS RELATING TO ALZHEIMER'S DISEASE
Disclosed herein are methods of administering precision gene therapy, treating and/or preventing Alzheimer' disease progression, and reducing expression of APOE and APOE e4. Disclosed herein are isolated nucleic acid molecules, viral vectors, lentiviral vectors, pharmaceutical formulations, host cells, guide RNAs and plasmids for use in the disclosed methods.
C12Q 1/6809 - Méthodes de détermination ou d’identification des acides nucléiques faisant intervenir la détection différentielle
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
23.
COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (Royaume‑Uni)
Inventeur(s)
Haynes, Barton F.
Li, Dapeng
Azoitei, Mihai
Walters, Lucy C.
Gillespie, Geraldine
Brackenridge, Simon
Mcmichael, Andrew James
Saunders, Kevin O.
Abrégé
Recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E-peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK and/or CD8+ T-cells positive for cell-surface expression of NKG2A ("NKG2A+"). Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from HLA-E-VL9 peptide-immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The invention provides methods for using HLA-E-VL9 m Abs to modulate NK and/or CD8+T-cell function as part of immunotherapeutic strategies.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Sempowski, Gregory
Haynes, Barton F.
Saunders, Kevin
Li, Dapeng
Lu, Xiaozhi
Edwards, Robert J.
Acharya, Priyamvada
Manne, Kartik
Gobeil, Sophie
Mascola, John R.
Graham, Barney S.
Zhou, Tongqing
Abrégé
Recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to coronavirus spike protein. Herein, monoclonal antibodies were recombinantly derived from isolated B cell from coronavirus infected individuals. Such antibodies bind various epitopes on the coronavirus spike protein and are neutralizing. The invention provides methods for using the inventive antibodies in prophylactic and/or therapeutic methods to prevent or treat coronavirus infection.
Method and apparatuses for forming gel droplets including biological tissue (e.g., cells), and in particular, methods and apparatuses for removing oil from the gel droplets comprising dissociated cells (including micro-organospheres) are described herein. Although it is beneficial to use oil in the formation of these gel droplets, and particularly micro-organospheres, oil may inhibit growth and survival of the cells within the gel droplets. The methods and apparatuses described herein may permit the removal of oil and may enhance survival and quality of the resulting gel droplets.
Aspects of the present disclosure describe techniques that involve an active stabilization of coherent controllers using nearby qubits. In an aspect, a quantum information processing (QIP) system for stabilizing phase damping in qubits is described that provides a first and a second qubit ion, measuring magnetic field fluctuations using the second qubit ion, and generates one or more magnetic fields based on the measured magnetic field fluctuations, the one or more magnetic fields being applied near the first qubit ion to cancel the magnetic field fluctuations to stabilize the phase damping of the first qubit ion. Another such QIP system performs provides a first and a second qubit ion, locks a local oscillator to a frequency reference associated with the second qubit ion, and tracks, using the local oscillator, a frequency of the first qubit ion based on the frequency reference. Methods associated with these QIP systems are also described.
A voice therapy device including a body having an internal passageway with a longitudinal axis that defines an airflow direction; a mouthpiece positioned at a proximal end of the body; and a resistance portion positioned at a distal end of the body, where the resistance portion is adjustable to vary an airflow resistance through the internal passageway. In some embodiments, the voice therapy device includes a sensor electrically coupled to a processor. A system for voice therapy includes the voice therapy device and a software application.
A genetically engineered microbial strains and related bioprocesses for the production of products from acetyl-CoA. Specifically, the use of dynamically controlled synthetic metabolic valves to reduce the activity of certain enzymes, leads to increased product production in a two-stage process.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
A method for treating cachexia in a subject in need thereof includes stimulating the parasympathetic nervous system of the subject thereby treating cachexia in the subject. Stimulating the parasympathetic nervous system can increase expression of urea cycle enzymes in the liver of the subject. Parasympathetic nervous system stimulation can comprise stimulating the vagus nerve, for example, the cervical vagus nerve or the hepatic branch of the vagus nerve. Pulses can be delivered at a frequency ranging from 1 Hz to 10Hz or at a frequency of about 5 kHz.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61H 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
Described herein are hydrogels attached to a base with the strength and fatigue comparable to that of cartilage on bone and methods of forming them. The methods and apparatuses described herein may achieve an attachment strength between a hydrogel and a substrate equivalent to the osteochondral junction. In some examples the hydrogel may be a triple-network hydrogel (such as BC-PVA-PAMPS) that is attached to a porous substrate (e.g., a titanium base) with the shear strength and fatigue strength equivalent to that of the osteochondral junction.
A61L 27/48 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire avec des charges macromoléculaires
32.
ENHANCED CELL SURVIVAL AGAINST BIOTIC AND ABIOTIC STRESSES THROUGH SALICYLIC ACID-INDUCED NPR1 CONDENSATES
The present disclosure describes compositions and methods for promoting cell survival against biotic and abiotic stress and during plant immune responses.
Described herein are compositions and method for autologous adipose tissue grafting. In one embodiment, the composition comprises a recombinant partially ordered polypeptide (Fractomer) or "Fractomer" and adipose tissue from a subject. In one aspect, the Fractomer has the general structure of [(GXGVP)n-a-helix]m, where X can be any amino acid except proline and a-helix is any polyalanine based a-helix having about 5 to 50 Alanine residues. In another aspect, the Fractomer has the structure [(GXGVP)n-GX1(A)25X1]m; where X is A or V; X1 is K or D; n is an integer from 10 to 20; and m is an integer from 4 to 8.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
The present disclosure is related to genetically engineered microbial strains and related bioprocesses for the production of xylitol. Specifically, the use of dynamically controlled synthetic metabolic valves to reduce the activity of certain enzymes, leads to increased xylitol production in a two-stage process.
Disclosed herein are fusion proteins for the targeted activation of genes as well as compositions and methods and DMA Targeting Systems comprising the same. The fusion protein may include at least one first polypeptide domain and at least one second polypeptide domain. The first polypeptide domain includes a DMA binding protein, such as a zinc finger protein, a TALE, or a Cas protein, that targets the fusion protein for binding to a specific DNA sequence. The second polypeptide domain includes a modulator of chromatin structure. The fusion protein may further include a third polypeptide domain, the third polypeptide domain including a transcriptional activator domain.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
36.
COMPOSITIONS AND METHODS FOR FORMATION AND SECRETION OF EXTRACELLULAR VESICLES AND AAV PARTICLES
Disclosed herein are compositions and methods for enhancing secretion of extracellular vesicles and/or AAV particles from cells. Disclosed herein are compositions and methods for altering and/or modifying the formation and/or secretion of extracellular vesicles and/or AAV particles from cells. Disclosed herein are compositions and methods for loading extracellular vesicles and or AAV particles with a cargo. Disclosed herein are isolated nucleic acid molecules encoding a polypeptide for promoting the formation of extracellular vesicles and AAV particles in cell or a polypeptide associated with extracellular vesicles and/or AAV particles secreted from a cell.
The present disclosure provides adeno-associated virus (AAV) vectors, comprising coevolved capsid variant proteins, pharmaceutical compositions, methods of making, and methods for delivering such to a subject.
The invention provides SARS-2 spike protein designs and uses thereof. The invention relates, in general, to modified SARS-CoV-2 proteins, nucleic acids encoding these, methods of making recombinant proteins and nucleic acids, compositions comprising these and their use in vaccination regimens, and diagnostic assays.
CRISPR based interference has become common in various application form genetic circuits to dynamic metabolic control. In E. coli, the native CRISPR Cascade system can be utilized for silencing by deletion of the cas3 nuclease along with expression of guide RNA arrays, where multiple genes can be silenced from a single transcript.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
40.
COMPOSITIONS AND METHODS FOR CIRCULAR RNA EXPRESSION
The present disclosure provides nucleic acid molecules encoding for at least two circular RNA (circRNAs), adeno-associated virus (AAV) particles including nucleic acid molecules encoding for at least two circRNAs, pharmaceutical compositions, and methods for delivering such to a subject.
A method of monitoring viability of stem cell-derived cells used in stem cell therapy comprises introducing one or more stem cell-derived cells to a cell culture media, introducing one or more nanoprobes to the cell culture media, whereby the one or more stem cell-derived cells are transfected with the one or more nanoprobes, and detecting an optical signal from the one or more nanoprobes after transfection. The method may further comprise introducing the one or more transfected stem cell- derived cells to a subject and detecting the optical signal from the one or more nanoprobes in vivo. The one or more stem cell-derived cells may include a stem cell.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
Disclosed herein are methods for making a transcriptome-wide expression profile of a biological sample and identifying biomarkers that can be used to diagnose, monitor the onset, monitor the progression, and assess the recovery of a disease in a subject. The biomarkers can also be used to establish and evaluate treatment regimens.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
B01D 59/44 - Séparation par spectrographie de masse
C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p.ex. bibliothèques de gènes
43.
TREATMENT OF UTERINE FIBROIDS USING PURIFIED COLLAGENASE
The invention relates to compositions and methods for treating uterine fibroids in vivo, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroids is injected or inserted into the uterine fibroid. The invention also relates to methods of reducing symptoms associated with uterine fibroids, including pain, bleeding and infertility.
The present disclosure provides a newly-identified transitional cell state in alveolar regeneration, models to ablate lung alveolar type-1 cells that leads to lung fibrosis and emphysema, a scalable, an ex vivo lung fibrosis model that uses co-cultured lung fibroblasts and pre-alveolar type-1 transitional cell state (PATS) for the use of disease modeling and drug screening, and methods of using same.
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Parkin, Jacqueline
Sung, Anthony
Pavletic, Steven Z
Im, Annie
Holtzman, Noa G
Peer, Cody J.
Abrégé
The invention relates to treatments for organ rejection, in particular to treatments for lung transplant associated bronchiolitis obliterans syndrome by administering a neutrophil elastase inhibitor, such as alvelestat. The invention also relates to treatments for graft versus host disease.
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
47.
METHODS OF DETERMINING THE SUITABILITY OF CULTURED THYMUS TISSUE FOR IMPLANTATION INTO HUMANS AND ASSOCIATED METHODS OF USE
Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor. Methods of producing an allogeneic cultured postnatal thymus tissue-derived product suitable for implantation into a human; methods of culturing allogeneic cultured postnatal thymus tissue-derived product suitable for implantation into a human and methods of using allogeneic cultured postnatal thymus tissue-derived product by implantation in a human subject.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
48.
COMPOSITIONS AND METHODS FOR IDENTIFYING REGULATORS OF CELL TYPE FATE SPECIFICATION
Disclosed herein are compositions, methods, and systems for selecting a polynucleotide for activity as a neuronal-specific transcription factor. The system may include a polynucleotide encoding a reporter protein and a pan-neuronal marker, a Gas protein, and a library of guide RNAs (gRNAs) targeting putative transcription factors. Further provided are methods of screening for a neuronal-specific transcription factor.
C12N 9/96 - Stabilisation d'une enzyme par formation d'un adduct ou d'une composition; Formation de conjugaisons d'enzymes
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
49.
SKELETAL MYOBLAST PROGENITOR CELL LINEAGE SPECIFICATION BY CRISPR/CAS9-BASED TRANSCRIPTIONAL ACTIVATORS
Disclosed herein are methods and systems for increasing expression of Pax7, methods of activating endogenous myogenic transcription factor Pax7 in a cell, methods of differentiating a stem cell into a skeletal muscle progenitor cell, as well as compositions and methods for treating a subject in need of regenerative muscle progenitor cells. The compositions and methods may include a Cas9-based transcriptional activator protein and at least one guide RNA (gRNA) targeting Pax7.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
50.
COMPOSITIONS AND METHODS FOR BONE REPAIR AND BONE HEALTH
The present disclosure relates to polymer-based biomaterials for the systemic or localized delivery of osteoanabolic molecules, and their use in methods for treating and/or preventing bone degeneration and for promoting bone regeneration. In one aspect, the present invention provides a biomaterial comprising a polymer and a bioactive molecule binding moiety. In certain embodiments of the first aspect of the invention, the bioactive molecule binding moiety is an osteoanabolic molecule binding moiety.
A61K 47/24 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p.ex. cyclométhicone ou phospholipides
A61K 47/36 - Polysaccharides; Leurs dérivés, p.ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
The application is drawn to 18F-radiolabeled residualizing agents and biomolecules and methods for radiolabeling biomolecules with radioactive fluorine atoms. The biomolecules have an affinity for particular types of cells and may specifically bind a certain cell, such as a cancer cell. Relevant biomolecules include antibodies, monoclonal antibodies, antibody fragments, peptides, other proteins, nanoparticles and aptamers. The application further provides compositions including such labeled biomolecules, as well as methods of using the labeled biomolecules and/or compositions in imaging applications.
C07C 279/00 - Dérivés de la guanidine, c. à d. composés contenant le groupe les atomes d'azote liés par des liaisons simples ne faisant pas partie de groupes nitro ou nitroso
A61K 51/10 - Anticorps ou immunoglobulines; Leurs fragments
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
52.
METHODS AND APPARATUSES FOR PATIENT-DERIVED MICRO-ORGANOSPHERES
Micro-Organosphers, including Patient-Derived Micro-Organospheres (PMOSs), apparatuses and methods of making them, and apparatuses and methods of using them. Also described herein are methods and systems for screening a patient using these Patient-Derived Micro-Organospheres, including personalized therapies.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
The present disclosure provides nucleic acid expression cassettes, vectors, compositions and methods for the treatment of ATPase-mediated diseases in a subject.
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A method for promoting continuous sleep of a subject by eliminating and/or preventing sleep associations includes: (a) providing an apparatus including at least one sensor and at least one output device; (b) monitoring a state of the subject using the apparatus; (c) determining the subject is in an awake state using the at least one sensor; (d) in response to determining the subject is in the awake state, initiating and maintaining an output using the at least one output device; (e) determining the subject is in a sleep state using the at least one sensor; (f) halting the output in response to determining that the subject is in the sleep state such that the apparatus does not produce any output; (g) repeating at least step (b) during a sleep session. The method further includes modifying an intensity of the output over time until the intensity reaches zero.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61M 21/02 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscience; Dispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p.ex. pour mettre en état d'hypnose pour provoquer le sommeil ou la relaxation, p.ex. par stimulation directe des nerfs, par hypnose ou par analgésie
56.
MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRAL INFECTIONS
Provided are antibodies and antigen-binding fragments which bind to herpes simplex virus-2 (HSV-2), methods of use employing the antibodies and/or antigen-binding fragments, and pharmaceutical compositions comprising the antibodies and/or antigen-binding fragments.
Described herein are methods and composition for diagnosing and evaluating the treatment of depression using one or more biomarker metabolites for the diagnosis and monitoring treatment efficacy. In one aspect, the biomarker metabolites can be used to screen subjects for the likelihood of developing depression, the diagnosis thereof, monitoring the efficacy of treatment, and evaluating a subject's propensity for responding to treatment.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
The present invention provides compositions and methods related to the cell surface protein CRB1 for the treatment of retinopathies in a subject, as well as systems and kits employing such compositions.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
59.
COMPOSITIONS AND METHODS FOR EVADING HUMORAL IMMUNITY
The present disclosure provides, in part, compositions and methods for transient removal of neutralizing antibodies directed to AAV vectors. Such compositions and methods expand the patient cohort eligible for gene therapy and also for redosing/re-administration of AAV in patients previously treated with AAV vectors.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
Provided herein according to some embodiments is a method of treating acute neural injury in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Also provided is a method of treating vascular dementia in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Further provided is a method of treating CNS lupus in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II.
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
61.
QUINONE REDUCTASE 2 INHIBITOR COMPOUNDS AND USES THEREOF
Provided herein according to some embodiments is a compound of Formula (I): [Formula], or a pharmaceutically acceptable salt or prodrug thereof. Compositions comprising the compound, and uses thereof for inhibiting the activity of quinone reductase-2, as well as in methods of treatment, are also provided.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
62.
COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
The invention is directed to modified HIV-l envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-l envelopes and/or these nucleic acids to induce immune responses.
A61K 39/21 - Retroviridae, p.ex. virus de l'anémie infectieuse équine
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
C12N 7/04 - Inactivation ou atténuation; Production de parties élémentaires de virus
The technology is directed to HIV envelopes which comprise sequence modifications wherein these modifications prevent CD4-induced transitions of the HIV envelope. Specifically, the disclosure provides recombinant HIV-1 Env proteins comprising mutations, wherein the envelope is a protomer, and wherein three protomers form a trimer stabilized by the presence of the mutations. Provided also are compositions comprising envelopes of the technology, and methods of use.
A61K 39/21 - Retroviridae, p.ex. virus de l'anémie infectieuse équine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
64.
METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES
The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) "back of the eye" retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
The present disclosure relates to a chimeric antigen receptor (CAR) molecule that specifically binds LYPD3, and also provides compositions comprising CAR T-cell-derived effector cells specific for LYPD3 and methods of making and using same.
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
DYNAMIC HYPERPOLARIZED 129Xe GAS EXCHANGE SPECTROSCOPY Methods and systems for generating dynamic spectroscopy parameters from hyperpolarized 129Xe dynamic NMR free induction decay signals of lungs by fitting a function that includes one or more non-Lorentzian line shape, such as a Voigt line shape for fitting barrier resonance signal, and further signal processing for identifying parameters of cardiogenic oscillations and for use of these parameters for evaluating disease states, use in drug discovery or monitoring disease status.
G01R 33/56 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
A61B 5/08 - Dispositifs de mesure pour examiner les organes respiratoires
G01R 33/483 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p.ex. spectroscopie in vivo
G01R 33/485 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p.ex. spectroscopie in vivo basés sur l'information de déplacement chimique
67.
COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS WITH RIFAXIMIN
This invention relates generally to neurodegenerative diseases and conditions (e.g., Alzheimer's disease) characterized with higher than normal brain blood ammonia levels and/or higher than normal amounts of circulatory pro-inflammatory cytokines secreted by harmful gut bacteria. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions capable of reducing blood ammonia levels and/or reducing levels of circulatory pro-inflammatory cytokines secreted by harmful gut bacteria.
A61K 33/44 - Carbone élémentaire, p.ex. charbon de bois, noir de carbone
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
68.
SYSTEMS AND METHODS FOR GENETIC MANIPULATION OF AKKERMANSIA SPECIES
The present disclosure provides methods and systems for genetically altering and screening Akkermansia bacteria, including Akkermansia muciniphila. The methods also provide genetically altered bacteria, libraries of genetically altered bacteria and use of such bacteria for treatment of diseases.
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/04 - Détermination de la présence ou du type de micro-organisme; Emploi de milieux sélectifs pour tester des antibiotiques ou des bactéricides; Compositions à cet effet contenant un indicateur chimique
The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Domain and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispecific gp41-Binding Molecules (including bispecific diabodies (including DART® diabodies), BiTE®s, bispecific antibodies, trivalent binding molecules (including TRIDENT molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that comprise any of such gp41-Binding Molecules, and to methods involving the use of any of such gp41-Binding Molecules in the treatment of HIV-1 infection.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
70.
DOWNREGULATION OF SNCA EXPRESSION BY TARGETED EDITING OF DNA-METHYLATION
Disclosed herein are Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based epigenome modifier compositions for epigenomic modification of a SNCA gene and methods of use thereof.
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
Provided is a method of treating a tumor in an individual by neoadjuvant therapy, wherein the individual has not previously undergone treatment to effectively reduce tumor burden, the method comprising administering an oncolytic chimeric poliovirus construct, or an oncolytic chimeric poliovirus construct and an immune checkpoint inhibitor, followed by reduction of the tumor. The method may further comprise administration of immune checkpoint inhibitor or oncolytic chimeric poliovirus construct following reduction of tumor. Kits for performing the methods are also provided.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
The present disclosure provides methods of treating Autism Spectrum Disorder. More particularly, the present disclosure relates to methods of using cord blood tissue-derived mesenchymal stromal cells to treat Autism Spectrum Disorder.
The present invention relates to methods of treating cerebral palsy and hypoxic- ischemic encephalopathy using cord blood tissue-derived mesenchymal stromal cells.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
Disclosed herein are compositions and methods for cellular reprogramming. The compositions comprise one or more miRs and an activator of NFkB. Also provided are methods for enhancing or upregulating cardiomyocyte maturation in a cell or a subject and methods for inhibiting or downregulating cardiomyocyte maturation.
Electronic identification tagging systems, methods, applicators, and tapes for tracking and managing medical equipment and other objects are disclosed. According to an aspect, a system includes electronic identification tag readers distributed within predetermined areas of an environment. The system also includes electronic identification tags attached to respective medical equipment within the environment. Further, the system includes a computing device comprising an object use analyzer configured to receive, from the electronic identification tag readers, information indicating presence of the electronic identification tags within the predetermined areas. The object use analyzer also analyzes usage of the medical equipment within the environment based on the received information. Further, the object use analyzer manages one of medical equipment supply or usage of the medical equipment during a medical procedure based on the analyzed usage of the medical equipment.
G06K 7/10 - Méthodes ou dispositions pour la lecture de supports d'enregistrement par radiation corpusculaire
G16H 40/40 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion d’équipement ou de dispositifs médicaux, p.ex. pour planifier la maintenance ou les mises à jour
76.
COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes and methods of using these modified HIV-1 envelopes to induce immune responses.
A61K 39/21 - Retroviridae, p.ex. virus de l'anémie infectieuse équine
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
77.
CULTURED THYMUS TISSUE TRANSPLANTATION PROMOTES DONOR-SPECIFIC TOLERANCE TO ALLOGENEIC SOLID ORGAN TRANSPLANTS
Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour le typage de tissu ou de cellule, p.ex. sondes d’antigène leucocytaire humain [HLA]
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
78.
PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing offtarget accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
C07D 257/02 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle non condensés avec d'autres cycles
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
79.
LOW-DOSE CARBIDOPA FOR ENHANCING 5-HYDROXYTRYPTOPHAN BIOAVAILABILITY
Provided are methods of enhancing bioavailability of enterally administered 5-hydroxytryptophan (5-HTP) in a subject in need thereof, said method comprising enterally co-administering low-dose carbidopa with said 5-HTP, as well as pharmaceutical formulations useful for the same. In some embodiments, the 5-HTP and/or low-dose carbidopa are provided as slow-release formulation(s).
A61K 31/136 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p.ex. benzène-amine
A61K 31/195 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino
A61K 31/405 - Acides indole-alkanecarboxyliques; Leurs dérivés, p.ex. tryptophane, indométhacine
80.
TRIPLE-NETWORK HYDROGEL IMPLANTS FOR REPAIR OF CARTILAGE
Artificial cartilage materials for repair and replacement of cartilage (e.g., load-bearing, articular cartilage). The artificial cartilage materials described herein include triple-network hydrogels including a cross-linked fiber network (e.g., a bacterial cellulose nanofiber network) and a double-network hydrogel (e.g., a double-network hydrogel including polfacrylamide-methyl propyl sulfonic acid). The artificial cartilage may be coated onto or formed into an implant (e.g., plug). The artificial cartilage may include a surface macroporosity, e.g., 0.1-300 micrometers diameter. Also described herein are methods of forming and methods of using the triple-network hydrogel artificial cartilage materials.
A61L 27/40 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
A61L 27/44 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent comportant une matrice macromoléculaire
A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
The present disclosure comprises devices, systems and methods for organizing cells into an array, phenotyping them via image-based analysis over short or long durations, and conducting massively parallel barcoded genomic analysis with DNA barcodes that are present next to each cell.
Provided herein are fluoro-substituted porphyrin compounds, such as those having a structure represented by Formula (I), wherein R1 is a C1-C8 alkyl that is substituted with at least 1 fluorine (e.g., a C1-C8 alkyl substituted with 1-17 fluorine atoms); and X is an anion (e.g. a halogen ion (e.g., chloride, etc.), PF6, tosylate, besylate, and/or mesylate). Also provided herein are methods of making the fluoro-substituted porphyrin compounds, pharmaceutical formulations containing the same, and methods of use thereof.
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p.ex. dérivés de la porphine, bilirubine, biliverdine
The present disclosure provides resonator networks adapted to a variety of applications. The networks include fluorophores, quantum dots, dyes, plasmonic nanorods, or other optical resonators maintained in position relative to each other by a backbone (e g , a backbone composed of DNA). The networks may exhibit optical absorption and re-emission according to specified temporal decay profiles, e.g., to provide temporally -multiplexed labels for imaging or flow cytometry. The networks can include resonators that exhibit a dark state, such that the behavior of the network can be modified by inducing the dark state in one or more resonators. Such networks could be configured as logic gates or other logical elements, e.g., to provide multiplexed detection of analytes by a single network, to permit the temporal decay profile of the network to be adjusted (e.g., to use the networks as a controllable random number generator), or to provide other benefits.
C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
84.
X-RAY PSORALEN ACTIVATED CANCER THERAPY (X-PACT) WITH ASSOCIATED TREATMENTS
A system (and associated method) for treating a human or animal body The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carner including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carner, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy mto the body, and a supplemental treatment device which admmisters one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
The invention is directed to immunogens and methods for inducing immune responses, comprising methods for germline B cell stimulation and maturation by reverse engineering of HIV- 1 envelopes.
Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
87.
COMPOSITIONS AND METHODS FOR DIFFERENTIAL INDUCTION OF CELL DEATH AND INTERFERON EXPRESSION
Disclosed herein are compositions and methods for inhibiting the growth of cells or inducing cell death. The composition capable of inhibiting the growth of cells or inducing cell death comprises a 5'-triphosphate non-linear RNA. The RNA comprises a first stem- loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and may optionally comprise a second stem-loop formed from the complete or partial hybridization of at least 8 nucleotide pairings and a spacer between the first stem-loop and the second stem loop. Methods for inhibiting the growth of cells or inducing cell death comprise contacting cells with the composition or administering the composition to a subject in an amount effective to inhibit the growth of the cells or induce death of the cells.
In certain aspects the invention provides HIV-1 immunogens, including envelopes (CH0848) and selections therefrom, and methods for swarm immunizations using combinations of HIV- 1 envelopes.
The present disclosure provides compositions and methods for rapid production of chemicals in genetically engineered microorganisms in a large scale. Also provided herein is a high-throughput metabolic engineering platform enabling the rapid optimization of microbial production strains. The platform, which bridges a gap between current in vivo and in vitro bio-production approaches, relies on dynamic minimization of the active metabolic network.
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
The invention generally relates to compositions (including constructs, vectors, and cells) and methods of using such compositions for controlling gene expression. More specifically, the invention relates to use of R-motif sequences and/or uORF sequences to control gene expression.
Described are oxysterols, pharmaceutical compositions including the oxvsterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to inflammation, such as necrotizing enterocolitis, mesenteric ischemia, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, lymphocytic colitis, Celiac disease, Behcet's disease, rheumatoid arthritis, psoriasis, and autoimmune thyroid disease.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p.ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
92.
METHODS OF MAKING SUBSTITUTED PORPHYRIN PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS
Described herein are methods and intermediates useful for making substituted porphyrins, including Mn(III) ortho N-butoxyethylpyridylporphyrin, and compositions comprising the same. In some embodiments, a method of the present invention provides a composition having a certain percentage or yield (e.g., at least 80%, 85%, 90%, or 95% by weight) of a compound of the present invention.
C07B 47/00 - Formation ou introduction de groupes fonctionnels non prévus par les groupes
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
The invention is directed to methods to identify improbable mutations in the heavy or light chain variable domain of an antibody, methods to identify antigens which bind to antibodies comprising such improbable mutations, and methods of using such antigens to induce immune responses.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
INSERM - INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
ASSOCIATION INSTITUT DE MYOLOGIE (France)
Inventeur(s)
Mingozzi, Federico
Ronzitti, Giuseppe
Koeberl, Dwight D.
Han, Sang-Oh
Abrégé
The present invention relates to variants of acid-alpha glucosidase and uses thereof. Said variants are sequence-optimized and/or are linked to a heterogenous signal peptide.
Chimeric poliovirus is capable of activating antigen presenting cells. The activation of the antigen presenting cells may be in vitro, ex vivo, or in vivo. The activated antigen presenting cells may be administered alone or with an antigen or vaccine. The activated antigen may be loaded in vitro or ex vivo with antigen to form antigen-loaded, activated, antigen presenting cells. These may be administered therapeutically. Therapeutic administration of antigen presenting cells may be used as an adjuvant to other therapies.
A warp knitted fabric formed by a warp knitting machine includes a first knitted portion formed using a first knitting sequence in a machine direction, the first knitted portion comprises at least two strips extending in the machine direction, the at least two strips being detached from one another along their lengthwise edges. The second knitted portion has the same width as the first knitted portion, and the first knitted portion and the second knitted portion alternate sequentially in the machine direction and are formed of a single set of continuous textile strands.
D04B 21/00 - Procédés de tricotage chaîne pour la production de tricots ou articles qui ne dépendent pas de l'emploi de machines particulières; Tricots ou articles définis par de tels procédés
This disclosure relates to methods of regulating growth in a plant. Specifically, the methods of the disclosure regulate growth of the plant by administration of a composition comprising an effective amount of one or more apocarotenoids to the plant, its part, or the seed.
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
A01N 43/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome
99.
BENZOYLGLYCINE DERIVATIVES AND METHODS OF MAKING AND USING SAME
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
Inventeur(s)
Zhou, Pei
Toone, Eric J.
Gopalaswamy, Ramesh
Navas, Frank, Iii
Nicholas, Robert A.
Liang, Xiaofei
Abrégé
Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1,R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
C07C 229/22 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé le squelette carboné étant substitué de plus par des atomes d'oxygène
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61K 31/382 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à six chaînons, p.ex. thioxanthènes
A61K 31/396 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à trois chaînons, p.ex. aziridine
A61K 31/54 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p.ex. sulthiame
A61K 31/7032 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un polyol, c. à d. composés ayant plusieurs groupes hydroxyle, libres ou estérifiés, y compris le groupe hydroxyle impliqué dans la liaison glycosidique, p.ex. monoglucosyl-diacylglycérides, acide lactobionique, gangliosides
C07C 227/12 - Formation de groupes amino et carboxyle
C07C 259/06 - Composés contenant des groupes carboxyle, un atome d'oxygène d'un groupe carboxyle étant remplacé par un atome d'azote, cet atome d'azote étant lié de plus à un atome d'oxygène et ne faisant pas partie de groupes nitro ou nitroso sans remplacement de l'autre atome d'oxygène du groupe carboxyle, p.ex. acides hydroxamiques ayant des atomes de carbone de groupes hydroxamique liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
C07C 317/18 - Sulfones; Sulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
C07D 203/08 - Composés hétérocycliques contenant des cycles à trois chaînons ne comportant qu'un seul atome d'azote comme unique hétéro-atome du cycle non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement à l'atome d'azote du cycle
C07D 263/16 - Composés hétérocycliques contenant des cycles oxazole-1, 3 ou oxazole-1, 3 hydrogéné non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 277/40 - Radicaux amino ou imino non substitués
C07D 295/155 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de car avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile avec les atomes d'azote du cycle et les atomes de carbone comportant trois liaisons à des hétéro-atomes séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
C07D 309/04 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydro-carbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
C07D 335/02 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome de soufre comme unique hétéro-atome du cycle non condensés avec d'autres cycles
100.
MANGANESE COMPLEXES WITH SUBSTITUTED BISPHOSPHONATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS
Provided herein is a compound useful as a magnetic resonance imaging (MRI) contrast agent and a therapeutic agent, said compound having a structure represented by: Y X Z wherein, X is Mn(II), and Y and Z are each independently a bisphosphonate coupled to one or more therapeutic agents. Methods of use of the compound for MRI imaging and treatment for cancer or a microbial infection are also provided.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire (RMN); Préparations de contraste pour l'imagerie par résonance magnétique (IRM) caractérisées par le support
brevets
